Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 04/26 05:35:12 pm
18.46 EUR   -0.75%
04/24PCAS : Chiffre d'affaires au 31 Mars 2018
PU
04/24PCAS : Net sales as of march 31, 2018
GL
02/20PCAS : 2017 Annual Results
GL
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

PCAS : Extension of the manufacturing between VLG Chem and Sanofi

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/29/2011 | 11:11am CEST
Extension of the manufacturing contract between VLG Chem and  Sanofi until 2015 The PCAS Group and the Sanofi Group have signed an agreement on the extension of the manufacturing contract related to VLG Chem, a 100% PCAS subsidiary, until 2015. About PCAS PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.
Longjumeau, december 27th, 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
04/24PCAS : Chiffre d'affaires au 31 Mars 2018
PU
04/24PCAS : Net sales as of march 31, 2018
GL
02/20PCAS : 2017 Annual Results
GL
02/15PCAS SA : annual earnings release
01/31PCAS : Net sales as of December 31, 2017
PU
01/31PCAS : Net sales as of december 31, 2017
GL
01/31PCAS : Net sales as of december 31, 2017
AQ
2017PCAS : Chiffre d'affaires au 30 septembre 2017
PU
2017PCAS : Résultats au 1er semestre 2017
PU
2017NOMBRE TOTAL DE DROITS DE VOTE ET D' : Août 2017
PU
More news
Financials (€)
Sales 2018 227 M
EBIT 2018 20,6 M
Net income 2018 10,2 M
Debt 2018 47,9 M
Yield 2018 -
P/E ratio 2018 25,66
P/E ratio 2019 22,82
EV / Sales 2018 1,46x
EV / Sales 2019 1,37x
Capitalization 283 M
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 18,8 €
Spread / Average Target 0,81%
EPS Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Pierre Luzeau Chairman
Pierre Schreiner Chief Operating Officer
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Scientific Director
Sector and Competitors
1st jan.Capitalization (M$)
PCAS2.65%345
JOHNSON & JOHNSON-9.68%338 522
PFIZER2.32%220 455
NOVARTIS-8.69%202 567
ROCHE HOLDING LTD.-11.66%193 904
MERCK AND COMPANY5.97%161 967